Over two in five (42%) or approximately 57.4 million adults under the age of 65 with private insurance may qualify under clinical criteria for GLP-1 medications, which are used to manage type 2 diabetes, obesity, or weight-related health concerns, according to a recent analysis by KFF.

Despite only about 3% of adults with employer-sponsored insurance obtaining a prescription in 2022, the interest and expenditure on GLP-1 drugs have risen significantly and may continue to increase. Due to the high costs and growing demand for these medications, employers and insurers might further tighten the eligibility criteria for coverage beyond the clinical guidelines established by the Food and Drug Administration.

For a comprehensive analysis and additional health cost data, please visit the Peterson-KFF Health System Tracker, an online resource dedicated to evaluating and monitoring the U.S. health system’s performance.